LCI VS ALRN Stock Comparison

PerformanceForecastTechnicalsEarningsProfitVolatilityAnalyst Price Targets
PerformanceForecastTechnicalsEarningsProfitVolatilityAnalyst Price Targets

Performance

LCI
10/100

LCI returned -74.42% in the last 12 months. Based on the other stocks in its sector with an average return of -23.90%, its performance is below average giving it a grade of 10 of 100.

ALRN
10/100

ALRN returned -54.46% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Forecast

LCI
64/100

7 analysts offer 12-month price forecasts for LCI. Together, they have an average target of 0, the most optimistic forecast put LCI at 0 within 12-months and the most pessimistic has LCI at 0.

ALRN

"Forecast" not found for ALRN

Technicals

LCI
21/100

LCI receives a 21 of 100 based on 14 indicators. 3 are bullish, 11 are bearish.

ALRN
50/100

ALRN receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.

Earnings

LCI
10/100

LCI has missed earnings 9 times in the last 20 quarters.

ALRN
10/100

ALRN has missed earnings 9 times in the last 20 quarters.

Profit

LCI
10/100

Out of the last 4 quarters, LCI has had 0 profitable quarters and has increased their profits year over year on 0 of them.

ALRN
10/100

Out of the last 20 quarters, ALRN has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

LCI
48/100

LCI has had a lower than average amount of volatility over the last 12 months giving it a grade of 47 of 100.

ALRN
59/100

ALRN has had a higher than average amount of volatility over the last 12 months giving it a score of 59 of 100.

Analyst Price Targets

LCI

"Analyst Price Targets" not found for LCI

ALRN
100/100

4 analysts offer 12-month price targets for ALRN. Together, they have an average target of 0, the most optimistic target put ALRN at 0 within 12-months and the most pessimistic has ALRN at 0.

All score calculations are broken down here to help you make more informed investing decisions

Lannett Company, Inc. Summary

New York Stock Exchange / LCI
Healthcare
Drug Manufacturers—Specialty & Generic
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's primary products include Levothyroxine Sodium tablets, Fluphenazine tablets, Posaconazole DR tablets, Verapamil SR tablets, Methylphenidate CD capsules, Omeprazole capsules, Pantoprazole Sodium DR tablets, Sumatriptan Nasal spray, Metolazone tablets, Amphetamine IR Tablets, Methylphenidate Hydrochloride ER stimulants, as well as cocaine hydrochloride solution. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with Summit Bioscience LLC, HEC Group of companies, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies. Lannett Company, Inc. was incorporated in 1942 and is headquartered in Trevose, Pennsylvania.

Aileron Therapeutics, Inc. Common Stock Summary

Nasdaq / ALRN
Healthcare
Biotechnology
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.